Treatment of cystic diseases

1. A method for reducing electrolyte and fluid secretion in a patient having or suspected of having a cystic disease, the method comprising the step of administering to the patient (a) an effective amount of one or more TMEM16a inhibitors; and (b) an effective amount of one or more lysophosphatidic acid antagonists, or an effective amount of one or more PPAR gamma agonists, or a combination thereof.

2. The method of claim 1 wherein the one or more lysophosphatidic acid antagonists are selected from the group consisting of DGPP, cyclic sulfuric acid analogs of 2-oleoyl LPA, Ki16425, L-NASPA, VPC 12204, VPC 12249, VPC 12249-10t, VPC 12249-10t-13d, VPC 32179, VPC 32183, VPC 12031, Thio-ccPA-18:1, Thio-ccPA-16:0, CHF-ccPA, Palmitoyl α-bromomethylene phosphonate, Palmitoyl α-chloromethylene phosphonate, Palmitoyl α-H2-methylene phosphonate, Palmitoyl α-OH-methylene phosphonate, Oleoyl sn-2-AO-LPA, Palmitoyl sn-2-AO-LPA, Alkoxymethylene-phosphonate-LPA (18:1), Alkoxymethylene-phosphonate-LPA (16:0), FAP-10, FAP-12, SPH, SPP, N-palmitoyl-l-serine, N-palmitoyl-l-tyrosine, 2-Amino-3-oxo-3-(tetradeeylamino) propyl dihydrogen phosphate, 2-(Acetylamino)-3-oxo-3-(tetradecylamino) propyl dihydrogen phosphate, 2-Amino-3-(octadecylamino)-3-oxopropyl dihydrogen phosphate, 1,2-(3-Octadecyloxypropane)-bis (dihydrogen phosphate), 1,2-(3-Docosanoyloxypropane)-bis (dihydrogen phosphate), Phosphoric acid monobutyl ester, Phosphoric acid monooctyl ester, Phosphoric acid monooctadecyl ester, Phosphoric acid monodocosyl ester, Acyl LPG 18:1, DPIEL, LPG 14:0, 2(s)-OMPT, 3-(N-((2-(2-((pyridin-3-ylmethylamino) carbonyl)phenyl)phenyl)carbonyl)-N-(2-(2,5-dimethoxyphenyl-)ethyl)amino) propanoic acid hydrochloride, methyl 3-(14-[4-(1[1-(2-chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-5-isoxazolyl]benzyl}sulfanyl)propanoate, and 4′-1[(3-phenylpropyl) (3,4,5-imethoxybenzoyl)amino]methyl}-2-biphenylyl)acetic acid, and pharmaceutically acceptable salts of the foregoing.

3. The method of claim 1 wherein one of the lysophosphatidic acid antagonists is VPC 32183, or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 wherein at least one of the lysophosphatidic acid antagonists reduces the activity of lysophosphatidic acid at one or more lysophosphatidic acid receptors selected from the group consisting of LPA1, LPA2, LPA3, LPA4, and LPA5.

5. The method of claim 1 wherein one of the TMEM16a inhibitors is tannic acid or a pharmaceutically acceptable salt thereof, or a prodrug of any of the foregoing.

6. The method of claim 1 wherein the cystic disease is selected from the group consisting of polycystic kidney disease, Bardt Biedl syndrome, nephronophthisis, Meckel Gruber syndrome, and oral-facial-digital syndrome.

7. The method of claim 1 wherein the patient in need thereof has a cyst residing in an internal organ selected from the group consisting of kidney, liver, and pancreas.

8. The method of claim 1 wherein the lysophosphatidic acid antagonist is administered orally, parenterally, or by injection.

9. The method of claim 8 wherein the lysophosphatidic acid antagonist is administered by a method selected from the group consisting of intravenous injection, intrahepatic injection, intrarenal injection, intrapancreatic injection, direct infusion, and combinations thereof.

10. The method of claim 1 wherein the lysophosphatidic acid antagonist is administered via an implanted device.

11. The method of claim 1 wherein one of the lysophosphatidic acid antagonists is VPC 51299.